Illumina, a company specializing in DNA sequencing technology, has seen its stock price rise significantly, up approximately 160% from a low of $70 in October 2025. This increase comes after a tumultuous period marked by regulatory challenges, a failed acquisition of Grail, and management upheaval, including the ousting of its chairman and CEO.
Despite these setbacks, Illumina's stock has shown resilience, climbing steadily while the broader biotech sector struggles. Year-to-date, the stock has returned 74.5%, outperforming the S&P 500's 11.2% gain. The company reported flat revenue of $4.34 billion in 2025, but forecasts suggest a modest growth of 6.5% for the current year.
Recent quarterly results showed a 9.5% increase in revenue, driven by a 31% growth in sequencing instruments, which are crucial for future consumables sales. Illumina's gross margin stands at 68.2%, with a solid operating margin of 22.5%.
The stock's technical indicators suggest it is in a breakout phase, with support levels around $215 and $200, indicating potential for further gains if it maintains its upward trajectory. Investors are advised to monitor these levels closely as the stock continues to show strength against market volatility